Intellia Therapeutics Files 8-K
Ticker: NTLA · Form: 8-K · Filed: May 28, 2025 · CIK: 1652130
| Field | Detail |
|---|---|
| Company | Intellia Therapeutics, Inc. (NTLA) |
| Form Type | 8-K |
| Filed Date | May 28, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulation-fd
Related Tickers: NTLA
TL;DR
Intellia Therapeutics filed an 8-K on 5/28/25 for Reg FD and other events. Details pending.
AI Summary
Intellia Therapeutics, Inc. filed an 8-K on May 28, 2025, to report on events that occurred on the same date. The filing indicates it is for a Regulation FD Disclosure and Other Events, with no specific details on the nature of these events provided in the excerpt.
Why It Matters
This 8-K filing signals that Intellia Therapeutics has made a disclosure to the SEC regarding significant events. Investors should review the full filing for details on what these events entail.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not inherently present new risks, but the content of the disclosure could be material.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- May 28, 2025 (date) — Date of Report
FAQ
What specific events are being disclosed in this 8-K filing?
The provided excerpt does not specify the exact events, only that they fall under Regulation FD Disclosure and Other Events.
When was this 8-K filing submitted?
The filing was submitted on May 28, 2025.
What is the exact name of the company filing this report?
The exact name of the company is Intellia Therapeutics, Inc.
What is the principal executive office address for Intellia Therapeutics, Inc.?
The address is 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is the IRS Employer Identification Number for Intellia Therapeutics, Inc.?
The IRS Employer Identification Number is 36-4785571.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding Intellia Therapeutics, Inc. (NTLA).